Year of drug’s first FDA- approval,FDA-approved drug(s) a,FDA drug label listed biomarker(s) b,Class of agent(s) c,Mechanism of action or drug target c,Genes,Targeted therapy,Precision oncology therapy,Can a DNA/NGS-based method be used for biomarker detection? 
1998-2001*,Alemtuzumab,,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD52-directed cytolytic antibody,,Y,N,NA
1998-2001*,Alitretinoin,,Retinoid,Vitamin A derivative; activates retinoid receptors PML-RAR?,PML-RAR,Y,N,NA
1998-2001*,Arsenic trioxide,PML-RAR? Fusion,Cytotoxic chemotherapy,Chemotherapeutic agent; targets PML-RAR?,PML-RAR,N,Y,Y
1998-2001*,Bexarotene,,Retinoid,Selective activator of retinoid X receptors (RXR)s,,Y,N,NA
1998-2001*,Capecitabine,,Nucleoside metabolic inhibitor,Nucleoside metabolic inhibitor,,N,N,NA
1998-2001*,Denileukin diftitox,CD25+,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD25-directed cytotoxin,IL2RA,Y,Y,N
1998-2001*,Epirubicin,,Cytotoxic chemotherapy,Anthracycline topoisomerase inhibitor,,N,N,NA
1998-2001*,Exemestane,ER+,Hormone therapy,Aromatase inhibitor,,Y,Y,N
1998-2001*,Gemtuzumab ozogamicin,CD33+,"Hematopoietic protein binding antibody, ADC or cytotoxin",Anti-CD33 antibody,CD33,Y,Y,N
2018,Lorlatinib,ALK+ (ALK Fusions),Small molecule kinase inhibitor,Multi-targeted kinase inhibitor (targets include ALK and ROS1 among others),ALK;ROS1,Y,Y,Y
1998-2001*,Temozolomide,,Cytotoxic chemotherapy,Alkylating agent,,N,N,NA
1998-2001*,Thalidomide,,Other Immunotherapy,Immunomodulatory drug,,N,N,NA
1998-2001*,Trastuzumab,HER2+ (ERBB2 Amplification),Monoclonal antibody,Anti-HER2 (ERBB2) antibody,ERBB2,Y,Y,Y
1998-2001*,Triptorelin,,Hormone therapy,Gonadotropin-releasing hormone (GnRH) agonist,,Y,N,NA
1998-2001*,Valrubicin,,Cytotoxic chemotherapy,Anthracycline,,N,N,NA
2002,Fulvestrant,HR+/ HER2-,Hormone therapy,Selective estrogen receptor degrader (SERD),,Y,Y,N
2002,Ibritumomab tiuxetan,,"Hematopoietic protein binding antibody, ADC or cytotoxin",Anti-CD20 antibody,MS4A1,Y,N,NA
2002,Oxaliplatin,,Cytotoxic chemotherapy,Alkylating agent,,N,N,NA
2003,Abarelix,,Hormone therapy,Gonadotropin-releasing hormone (GnRH) antagonist,,Y,N,NA
2003,Bortezomib,,Proteasome inhibitors/protein synthesis inhibitor,Proteasome inhibitor,,Y,N,NA
2003,Gefitinib,"EGFR L858R, Exon 19 Deletions",Small molecule kinase inhibitor,EGFR tyrosine kinase inhibitor,EGFR,Y,Y,Y
2003,Tositumomab and Iodine I 131 Tositumomab,CD20+,"Hematopoietic protein binding antibody, ADC or cytotoxin",Anti-CD20 antibody,MS4A1,Y,Y,N
2004,Azacitidine,,Nucleoside metabolic inhibitor,Nucleoside metabolic inhibitor,,N,N,NA
2004,Bevacizumab,,Monoclonal antibody,Anti-VEGF antibody,VEGF,Y,N,NA
2004,Cetuximab,KRAS Wildtype and EGFR-expressing,Monoclonal antibody,Anti-EGFR antibody,EGFR,Y,Y,Y
2004,Clofarabine,,Nucleoside metabolic inhibitor,Nucleoside metabolic inhibitor,,N,N,NA
2004,Erlotinib,"EGFR L858R, Exon 19 Deletions",Small molecule kinase inhibitor,EGFR tyrosine kinase inhibitor,EGFR,Y,Y,Y
2004,Pemetrexed disodium,,Cytotoxic chemotherapy,Folate analog metabolic inhibitor,,N,N,NA
2005,Nelarabine,,Nucleoside metabolic inhibitor,Nucleoside metabolic inhibitor,,N,N,NA
1998-2001*,Imatinib,"*Ph+ (BCR-ABL1 Fusion)
*KIT+
*PDGFRA, PDGFRB Fusions
*PDGFB Fusions
*FIP1L1-PDGFRA fusion",Multikinase inhibitor,"Multi-targeted kinase inhibitor (targets include BCR-ABL, KIT, PDGFRA)",KIT;PDGFRA;BCR-ABL,Y,Y,Y
2019,Pexidartinib,,Multikinase inhibitor,"Multi-targeted kinase inhibitor (targets include CSF1R, KIT and FLT3)",CSF1R;KIT;FLT3,Y,N,NA
2006,Decitabine,,Nucleoside metabolic inhibitor,Nucleoside metabolic inhibitor,,N,N,NA
2006,Lenalidomide,,Other Immunotherapy,Immunomodulatory drug,,N,N,NA
2006,Panitumumab,KRAS and NRAS Wildtype and EGFR-expressing,Monoclonal antibody,Anti-EGFR antibody,EGFR,Y,Y,Y
2019,Erdafitinib,"FGFR3-TACC3 Fusion, FGFR3-BAIAP2L1 Fusion, FGFR3 S249C, R248C, G370C, Y373C",Small molecule kinase inhibitor,Multi-targeted kinase inhibitor (targets include FGFR1/2/3/4 among others),FGFR1;FGFR2;FGFR3;FGFR4,Y,Y,Y
2006,Vorinostat,,HDAC inhibitor,Histone deacetylase (HDAC) inhibitor,HDAC,Y,N,NA
2007,Ixabepilone,,Cytotoxic chemotherapy,Microtubule inhibitor,,N,N,NA
2007,Lapatinib,HER2 Overexpression (ERBB2 Amplification),Small molecule kinase inhibitor,Dual tyrosine kinase inhibitor (targets EGFR and ERBB2),EGFR;ERBB2,Y,Y,Y
2017,Midostaurin,"FLT3 ITD Mutations, TKD Mutations I836 and D835",Multikinase inhibitor,"Multi-targeted kinase inhibitor (targets include FLT3, VEGFR2, KIT and PDGFR)",FLT3;KDR;KIT;PDGFR,Y,Y,Y
2007,Temsirolimus,,Large molecule inhibitor,mTOR inhibitor,MTOR,Y,N,NA
2008,Bendamustine hydrochloride,,Cytotoxic chemotherapy,Alkylating agent,,N,N,NA
2008,Degarelix,,Hormone therapy,Gonadotropin-releasing hormone (GnRH) antagonist,,Y,N,NA
2009,Everolimus,"TSC1, TSC2 Oncogenic Mutations",Large molecule inhibitor,mTOR inhibitor,MTOR,Y,Y,Y
2009,Ofatumumab,,"Hematopoietic protein binding antibody, ADC or cytotoxin",Anti-CD20 antibody,MS4A1,Y,N,NA
2019,Fedratinib,,Multikinase inhibitor,Multi-targeted kinase inhibitor (targets include JAK2 and FLT3),JAK2;FLT3,Y,N,NA
2009,Pralatrexate,,Cytotoxic chemotherapy,Folate analog metabolic inhibitor,,N,N,NA
2009,Romidepsin,,HDAC inhibitor,Histone deacetylase (HDAC) inhibitor,HDAC,Y,N,NA
2010,Cabazitaxel,,Cytotoxic chemotherapy,Microtubule inhibitor,,N,N,NA
2010,Eribulin,,Cytotoxic chemotherapy,Microtubule inhibitor,,N,N,NA
2010,Sipuleucel-T,,Other Immunotherapy,Autologous cellular immunotherapy,,N,N,NA
2011,Abiraterone,,Hormone therapy,Antiandrogen; CYP17 inhibitor,CYP17A1,Y,N,NA
2011,Asparaginase erwinia chrysanthemi,,Other,Asparagine-specific enzyme,,N,N,NA
2011,Brentuximab,CD30+,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD30-directed antibody-drug conjugate,TNFRSF8,Y,Y,N
2020,Avapritinib,"*PDGFRA Exon 18 Mutations
*KIT D816",Small molecule kinase inhibitor,"Multi-targeted kinase inhibitor (targets include KIT D816V, PDGFRA, PDGFRA D842, KIT exon 11, 11/17 and 17 mutants)",KIT;PDGFRA,Y,Y,Y
2011,Ipilimumab,,Immune checkpoint inhibitor,Anti-CTLA-4 antibody,CTLA4,Y,N,NA
2011,Peginterferon alfa-2b,,Interferon/cytokine/chemokine,Alpha interferon,,N,N,NA
2011,Ruxolitinib,,Small molecule kinase inhibitor,JAK1/2 inhibitor,JAK1;JAK2,Y,N,NA
2019,Entrectinib,"*NTRK1, NTRK2, NTRK3 Fusions
*ROS1 Fusions",Small molecule kinase inhibitor,"Multi-targeted kinase inhibitor (targets include NTRK1/2/3, ROS1 and ALK among others)",NTRK1;NTRK2;NTRK3;ROS1;ALK,Y,Y,Y
2011,Vemurafenib,BRAF V600,Small molecule kinase inhibitor,BRAF inhibitor,BRAF,Y,Y,Y
2012,Aflibercept,,Other,VEGF inhibitor; VEGF-Trap,VEGF,Y,N,NA
2012,Axitinib,,Multikinase inhibitor,VEGFR1/2/3 inhibitor,FLT1;KDR;FLT3,Y,N,NA
2021,Umbralisib,,Multikinase inhibitor,Multi-targeted kinase inhibitor (targets include PI3K? and CK1? among others),PI3K;CSNK1A1,Y,N,NA
2023,Repotrectinib,"*ROS1 Fusions 
*NTRK Fusions",Small molecule kinase inhibitor,Multi-targeted kinase inhibitor (targets include ROS1 and NTRK1/2/3),ROS1;NTRK1;NTRK2;NTRK3,Y,Y,Y
2012,Carfilzomib,,Proteasome inhibitors/protein synthesis inhibitor,Proteasome inhibitor,,Y,N,NA
2012,Enzalutamide,,Hormone therapy,Antiandrogen; AR inhibitor,,Y,N,NA
2012,Omacetaxine mepesuccinate,,Proteasome inhibitors/protein synthesis inhibitor,Cephalotaxine ester and protein synthesis inhibitor,,Y,N,NA
2012,Pertuzumab + Trastuzumab,HER2+ (ERBB2 Amplification),Monoclonal antibody combination,Anti-HER2 (ERBB2) antibody + Anti-HER2 (ERBB2) antibody,ERBB2,Y,Y,Y
2006,Dasatinib,Ph+ (BCR-ABL1 Fusion),Multikinase inhibitor,"Multi-targeted kinase inhibitor (targets include SRC, BCR-ABL1, KIT and PDGFR? among others)",SRC;BRC-ABL1;KIT;PDGFR,Y,Y,Y
2005,Sorafenib,,Multikinase inhibitor,"Multi-targeted kinase inhibitor (targets include VEGFR1/2/3, BRAF, KIT, FLT3 and PDGFR? among others)",FLT1;KDR;FLT3;BRAF;KIT;FLT3;PDGFR,Y,N,NA
2012,Vismodegib,,Small molecule inhibitor,SMO inhibitor,SMO,Y,N,NA
2013,Ado-trastuzumab emtansine,HER2+ (ERBB2 Amplification),Antibody drug conjugate,HER2 (ERBB2)-directed antibody and microtubule inhibitor conjugate,ERBB2,Y,Y,Y
2013,Afatinib,"EGFR L858R, G719X, L861Q, S768I, Exon 19 Deletions",Small molecule kinase inhibitor,EGFR tyrosine kinase inhibitor,EGFR,Y,Y,Y
2013,Dabrafenib,BRAF V600E/K,Small molecule kinase inhibitor,BRAF inhibitor,BRAF,Y,Y,Y
2013,Ibrutinib,17p del,Small molecule kinase inhibitor,BTK inhibitor,BTK,Y,Y,Y
2013,Obinutuzumab,,"Hematopoietic protein binding antibody, ADC or cytotoxin",Anti-CD20 antibody,MS4A1,Y,N,NA
2013,Pomalidomide,,Other Immunotherapy,Immunomodulatory drug; Thalidomide analog,,N,N,NA
2013,Ra 223 dichloride,,Radiotherapy,Alpha particle-emitting radioactive therapeutic agent,,N,N,NA
2013,Trametinib,BRAF V600E/K,Small molecule kinase inhibitor,MEK1/2 inhibitor,MAP2K1;MAP2K2,Y,Y,Y
2014,Belinostat,,HDAC inhibitor,Histone deacetylase (HDAC) inhibitor,HDAC,Y,N,NA
2014,Blinatumomab,CD19+,Bispecific T-cell engager,Bispecific CD19-directed CD3 T-cell engager,CD19,Y,Y,N
2014,Ceritinib,ALK+ (ALK Fusions),Small molecule kinase inhibitor,ALK inhibitor,ALK,Y,Y,Y
2014,Dabrafenib + Trametinib,BRAF V600E/K,Small molecule kinase inhibitor combination,BRAF inhibitor + MEK1/2 inhibitor,BRAF;MAP2K1;MAP2K2,Y,Y,Y
2014,Idelalisib,,Small molecule inhibitor,PIK3K? inhibitor,PIK3K,Y,N,NA
2014,Lanreotide,,Hormone therapy,Somatostatin analog,,Y,N,NA
2014,Mercaptopurine,,Cytotoxic chemotherapy,Purine analog; interferes with nucleic acid synthesis,,N,N,NA
2014,Nivolumab,MSI-H,Immune checkpoint inhibitor,Anti-PD-1 antibody,PDCD1,Y,Y,Y
2014,Olaparib,"*BRCA1, BRCA2 Oncogenic Mutations  
*ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54 Oncogenic Mutations",Small molecule inhibitor,PARP inhibitor,PARP,Y,Y,Y
2014,Pembrolizumab,"*MSI-H or dMMR
*TMB-H
*PD-L1-expressing
*pMMR",Immune checkpoint inhibitor,Anti-PD-1 antibody,PDCD1,Y,Y,Y
2014,Ramucirumab,,Monoclonal antibody,Anti-VEGFR2 antibody,KDR,Y,N,NA
2014,Siltuximab,,Interferon/cytokine/chemokine,Interleukin-6 (IL-6) antagonist,IL6,N,N,NA
2015,Alectinib,ALK+ (ALK Fusions),Small molecule kinase inhibitor,ALK inhibitor,ALK,Y,Y,Y
2015,Vemurafenib + Cobimetinib ,BRAF V600E/K,Small molecule kinase inhibitor combination,BRAF inhibitor + MEK1/2 inhibitor,BRAF;MAP2K1;MAP2K2,Y,Y,Y
2015,Daratumumab,,"Hematopoietic protein binding antibody, ADC or cytotoxin",Anti-CD38 antibody,CD38,Y,N,NA
2015,Dinutuximab,,Monoclonal antibody,Anti-GD2 antibody,B4GALNT1,Y,N,NA
2015,Elotuzumab,,"Hematopoietic protein binding antibody, ADC or cytotoxin",Anti-SLAMF7 antibody,SLAMF7,Y,N,NA
2015,Ipilimumab + Nivolumab,"*MSI-H or dMMR
*PD-L1-expressing",Immune checkpoint inhibitor,Anti-CTLA-4 antibody + Anti-PD1 antibody,CTLA4;PDCD1,Y,Y,Y
2015,Ixazomib,,Proteasome inhibitors/protein synthesis inhibitor,Proteasome inhibitor,,Y,N,NA
2021,Tivozanib,,Multikinase inhibitor,"Multi-targeted kinase inhibitor (targets include VEGFR1/2/3, KIT and PDGFR?)",FLT1;KDR;FLT3;KIT;PDGFR,Y,N,NA
2015,Necitumumab,,Monoclonal antibody,Anti-EGFR antibody,EGFR,Y,N,NA
2015,Osimertinib,"EGFR T790M, L858R, Exon 19 Deletions",Small molecule kinase inhibitor,EGFR tyrosine kinase inhibitor with T790M,EGFR,Y,Y,Y
2015,Palbociclib,HR+/ HER2-,Small molecule kinase inhibitor,CDK4/6 inhibitor,CDK4;CDK6,Y,Y,N
2015,Panobinostat,,HDAC inhibitor,Histone deacetylase (HDAC) inhibitor,HDAC,Y,N,NA
2015,Sonidegib,,Small molecule inhibitor,SMO inhibitor,SMO,Y,N,NA
2015,Talimogene laherparepvec,,Other,Oncolytic viral therapy,,N,N,NA
2015,Trabectedin,,Cytotoxic chemotherapy,Alkylating agent,,N,N,NA
2015,Trifluridine/ tipiracil,,Nucleoside metabolic inhibitor,Nucleoside metabolic inhibitor/Thymidine phosphorylase inhibitor,,N,N,NA
2016,Atezolizumab,PD-L1-expressing,Immune checkpoint inhibitor,Anti-PDL-1 antibody,CD274,Y,Y,N
2016,Olaratumab,,Monoclonal antibody,Anti-PDGFR? antibody,PDGFR,Y,N,NA
2016,Rucaparib,"BRCA1, BRCA2 Oncogenic Mutations",Small molecule inhibitor,PARP inhibitor,PARP,Y,Y,Y
2016,Venetoclax,,Small molecule inhibitor,BCL-2 inhibitor,BCL2,Y,N,NA
2017,Abemaciclib,HR+/ HER2-,Small molecule kinase inhibitor,CDK4/6 inhibitor,CDK4;CDK6,Y,Y,N
2017,Acalabrutinib,,Small molecule kinase inhibitor,BTK inhibitor,BTK,Y,N,NA
2017,Avelumab,,Immune checkpoint inhibitor,Anti-PDL-1 antibody,CD274,Y,N,NA
2017,Axicabtagene ciloleucel,,CAR T-cell therapy,CAR T-cell therapy (CD-19 directed),CD19,Y,N,NA
2017,Brigatinib,ALK+ (ALK Fusions),Small molecule kinase inhibitor,ALK inhibitor,ALK,Y,Y,Y
2017,Copanlisib,,Small molecule inhibitor,PIK3K inhibitor,PIK3K,Y,N,NA
2017,Daunorubicin + Cytarabine,,Cytotoxic chemotherapy,Anthracycline topoisomerase inhibitor + nucleoside metabolic inhibitor,,N,N,NA
2017,Durvalumab,dMMR,Immune checkpoint inhibitor,Anti-PDL-1 antibody,,Y,Y,N
2017,Enasidenib,"IDH2 R140Q/L/G/W, R172G/K/M/S/W",Small molecule inhibitor,IDH2 inhibitor,IDH2,Y,Y,Y
2017,Inotuzumab Ozogamicin,CD22+,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD22-directed antibody-drug conjugate,CD22,Y,Y,N
2011,Crizotinib,"*ALK+ (ALK Fusions)
*ROS1+ (ROS1 Fusions)",Multikinase inhibitor,"Multi-targeted receptor tyrosine kinase inhibitor (targets include ALK, ROS1 and MET)",ALK;ROS1;MET,Y,Y,Y
2017,Neratinib,HER2+ (ERBB2 Amplification),Small molecule kinase inhibitor,EGFR//HER2 (ERBB2)/HER4 (ERBB4) inhibitor,EGFR;ERBB2;ERBB4,Y,Y,Y
2017,Niraparib,"BRCA1, BRCA2 Oncogenic Mutations",Small molecule inhibitor,PARP inhibitor,PARP,Y,Y,Y
2017,Ribociclib,HR+/ HER2-,Small molecule kinase inhibitor,CDK4/6 inhibitor,CDK4;CDK6,Y,Y,Y
2017,Tisagenlecleucel,,CAR T-cell therapy,CAR T-cell therapy (CD-19 directed),CD19,Y,N,NA
2018,Apalutamide,,Hormone therapy,Antiandrogen; AR inhibitor,AR,Y,N,NA
2018,Encorafenib + Binimetinib,BRAF V600E/K,Small molecule kinase inhibitor combination,BRAF inhibitor + MEK1/2 inhibitor,BRAF;MAP2K1;MAP2K2,Y,Y,Y
2018,Calaspargase pegol,,Other,Asparagine specific-enzyme,,N,N,NA
2018,Cemiplimab,PD-L1-expressing,Immune checkpoint inhibitor,Anti-PD-1 antibody,PDCD1,Y,Y,N
2018,Dacomitinib,"EGFR L858R, Exon 19 Deletions",Small molecule kinase inhibitor,EGFR tyrosine kinase inhibitor,EGFR,Y,Y,Y
2018,Duvelisib,,Small molecule inhibitor,PI3K?/? inhibitor,PI3K,Y,N,NA
2011,Vandetanib,,Multikinase inhibitor,"Multi-targeted receptor tyrosine kinase inhibitor (targets include VEGFR, EGFR and RET)",VEGFR;EGFR;RET,Y,N,NA
2018,Glasdegib,,Small molecule inhibitor,SMO inhibitor,SMO,Y,N,NA
2018,Iobenguane,,Radiotherapy,Radioactive therapeutic agent,,N,N,NA
2018,Ivosidenib,IDH1 R132C/G/H/L/S,Small molecule inhibitor,IDH1 inhibitor,IDH1,Y,Y,Y
2018,Larotrectinib,"NTRK1, NTRK2, NTRK3 Fusions",Small molecule kinase inhibitor,NTRK1/2/3 inhibitor,NTRK1;NTRK2;NTRK3,Y,Y,Y
2012,Cabozantinib,,Multikinase inhibitor,"Multi-targeted receptor tyrosine kinase inhibitor (targets include VEGFR1/2/3, AXL, KIT, RET and ROS1 among others)",FLT1;KDR;FLT3;AXL;KIT;RET;ROS1,Y,N,NA
2018,Lutetium Lu 177 dotatate,Somatostatin Receptor,Hormone therapy,Radiolabeled somatostatin analog,,Y,Y,N
2018,Mogamulizumab,,Interferon/cytokine/chemokine,Anti-CCR4 antibody,CCR4,N,N,NA
2018,Moxetumomab pasudotox,,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD22-directed antibody-drug conjugate,CD22,Y,N,NA
2018,Tagraxofusp,,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD123-directed cytotoxin,IL3RA,Y,N,NA
2018,Talazoparib,"*BRCA1, BRCA2 Oncogenic Mutations
*ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11, NBN, PALB2, RAD51C
Oncogenic Mutations",Small molecule inhibitor,PARP inhibitor,PARP,Y,Y,Y
2019,Alpelisib + Fulvestrant,"PIK3CA E545G, Q546E, E545A, H1047R, C420R, H1047Y, Q546R, H1047L, E542K, E545D, E545K",Small molecule inhibitor and hormone therapy combination,?-specific PI3K inhibitor + selective estrogen receptor degrader (SERD),PI3K;SERD,Y,Y,Y
2019,Darolutamide,,Hormone therapy,Antiandrogen; AR inhibitor,AR,Y,N,NA
2019,Enfortumab vedotin,,Antibody drug conjugate,Nectin-4-directed antibody and microtubule inhibitor conjugate,NECTIN4,Y,N,NA
2015,Lenvatinib,,Multikinase inhibitor,"Multi-targeted receptor tyrosine kinase inhibitor (targets include VEGFR1/2/3, FGFR1/2/3/4, KIT, RET and PDGFR? among others)",FLT1;KDR;FLT3;FGFR1;FGFR2;FGFR3;FGFR4;KIT;RET;PDGFR,Y,N,NA
2006,Sunitinib,KIT+,Multikinase inhibitor,"Multi-targeted receptor tyrosine kinase inhibitor (targets include VEGFR1/2/3, KIT, FLT3, CSF1R and PDGFR?/? among others)",FLT1;KDR;FLT3;KIT;FLT3;CSF1R;PDGFR,Y,Y,Y
2012,Bosutinib,Ph+ (BCR-ABL1 Fusion),Multikinase inhibitor,Multi-targeted tyrosine kinase inhibitor (targets include BCR-ABL1 and SRC family kinases),SRC;BRC-ABL1;KIT;PDGFR,Y,Y,Y
2007,Nilotinib,Ph+ (BCR-ABL1 Fusion),Multikinase inhibitor,"Multi-targeted tyrosine kinase inhibitor (targets include BCR-ABL1, PDGFR and KIT among others)",PDGFR;KIT,Y,Y,Y
2019,Polatuzumab vedotin,,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD79b-directed antibody-drug conjugate,CD79B,Y,N,NA
2019,Selinexor,,Small molecule inhibitor,Nuclear export inhibitor (XPO1 inhibitor),XPO1,Y,N,NA
2019,Trastuzumab deruxtecan,"*HER2+ (ERBB2 Amplification)
*HER2-low
*ERBB2 Oncogenic Mutations",Antibody drug conjugate,HER2 (ERBB2)-directed antibody and topoisomerase inhibitor conjugate,ERBB2,Y,Y,Y
2019,Zanubrutinib,,Small molecule kinase inhibitor,BTK inhibitor,BTK,Y,N,NA
2020,Atezolizumab + Vemurafenib + Cobimetinib,BRAF V600,Small molecule inhibitor and immune checkpoint inhibitor combination,Anti-PDL-1 antibody + BRAF inhibitor + MEK1/2 inhibitor,CD274;BRAF;MAP2K1;MAP2K2,Y,Y,Y
2012,Ponatinib,"Ph+ (BCR-ABL1 Fusion) or
ABL1 T315I",Multikinase inhibitor,"Multi-targeted tyrosine kinase inhibitor (targets include BCR-ABL1, VEGFR, PDGFR, FGFR and SRC family members among others)",VEGFR;PDGFR;FGFR;SRC,Y,Y,Y
2020,Belantamab mafodotin,,"Hematopoietic protein binding antibody, ADC or cytotoxin",BCMA-directed antibody-drug conjugate,TNFRSF17,Y,N,NA
2020,Brexucabtagene autoleucel,,CAR T-cell therapy,CAR T-cell therapy (CD-19 directed),CD19,Y,N,NA
2020,Capmatinib,MET Exon 14 Skipping Mutations,Small molecule kinase inhibitor,MET inhibitor,MET,Y,Y,Y
2020,Decitabine + Cedazuridine (INQOVI),,Cytotoxic chemotherapy,Nucleoside metabolic inhibitor + cytidine deaminase inhibitor,,N,N,NA
2020,Encorafenib + Cetuximab,BRAF V600E,Small molecule inhibitor and monoclonal antibody combination,BRAF inhibitor + Anti-EGFR antibody,BRAF;EGFR,Y,Y,Y
2020,Isatuximab,,"Hematopoietic protein binding antibody, ADC or cytotoxin",Anti-CD38 antibody,CD38,Y,N,NA
2020,Lurbinectedin,,Cytotoxic chemotherapy,Alkylating agent,,N,N,NA
2020,Margetuximab,HER2+ (ERBB2 Amplification),Monoclonal antibody,Anti-HER2 (ERBB2) antibody,ERBB2,Y,Y,Y
2020,Naxitamab,,Monoclonal antibody,Anti-GD2 antibody,B4GALNT1,Y,N,NA
2020,Pemigatinib,"*FGFR2 Fusions
*FGFR1 Fusions",Small molecule kinase inhibitor,FGFR1/2/3 inhibitor,FGFR1;FGFR2;FGFR3,Y,Y,Y
2020,Pralsetinib,RET Fusions and Oncogenic Mutations,Small molecule kinase inhibitor,"RET inhibitor (also reported to inhibit other kinases including DDR1, NTRK3, FLT3 and FGFR1/2 among others)",DDR1;RET;NTRK3;FLT3;FGFR1;FGFR2,Y,Y,Y
2020,Relugolix,,Hormone therapy,Gonadotropin-releasing hormone (GnRH) antagonist,,Y,N,NA
2020,Ripretinib,KIT/PDGFRA inhibitor,Small molecule kinase inhibitor,KIT/PDGFRA D816,KIT;PDGFRA,Y,Y,Y
2020,Sacituzumab govitecan,HR+/HER2-,Antibody drug conjugate,TROP2-directed antibody topoisomerase inhibitor conjugate,TACSTD2,Y,Y,N
2020,Selpercatinib,RET Fusions and Oncogenic Mutations,Small molecule kinase inhibitor,RET inhibitor (also reported to inhibit other kinases including VEGFR1/2/3 and FGFR1/2/3),RET;FLT1;KDR;FLT3;FGFR1;FGFR2;FGFR3,Y,Y,Y
2020,Selumetinib,NF1 Oncogenic Mutations,Small molecule kinase inhibitor,MEK1/2 inhibitor,MAP2K1;MAP2K2,Y,Y,Y
2020,Tafasitamab,,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD19-directed cytolytic monoclonal antibody,CD19,Y,N,NA
2020,Tazemetostat,"*EZH2 Y646F, A692V, Y646C, Y646S, Y646N, Y646H, A682G
*SMARCB1 Deletion",Small molecule inhibitor,EZH2 inhibitor (methyltransferase inhibitor),EZH2,Y,Y,Y
2020,Tucatinib + Trastuzumab,"*HER2+ (ERBB2 Amplifiaction)
*KRAS and NRAS Wildtype and HER2+ (ERBB2 Amplification)",Small molecule inhibitor and monoclonal antibody combination,HER2 (ERBB2) inhibitor + Anti-HER2 (ERBB2) antibody,ERBB2,Y,Y,Y
2021,Amivantamab,"*EGFR Exon 20 Insertions 
*EGFR Exon 19 Deletions, L858R",Monoclonal antibody,EGFR-MET bispecific antibody,EGFR,Y,Y,Y
2021,Asciminib,"Ph+ (BCR-ABL1 Fusion)
or ABL1 T315I",Small molecule kinase inhibitor,ABL/BCR-ABL1 tyrosine kinase inhibitor,ABL1,Y,Y,Y
2021,Belzutifan,VHL Oncogenic Mutations,Small molecule inhibitor,HIF-2? inhibitor,EPAS1,Y,Y,Y
2021,Dostarlimab,*dMMR                                                     *dMMR or MSI-H,Immune checkpoint inhibitor,Anti PD-1 antibody,PDCD1,Y,Y,Y
2021,Idecabtagene vicleucel,,CAR T-cell therapy,CAR T-cell therapy (BCMA-directed),TNFRSF17,Y,N,NA
2021,Infigratinib,FGFR2 Fusions,Small molecule kinase inhibitor,FGFR1/2/3 inhibitor,FGFR1;FGFR2;FGFR3,Y,Y,Y
2021,Lisocabtagene maraleucel,,CAR T-cell therapy,CAR T-cell therapy (CD-19 directed),CD19,Y,N,NA
2021,loncastuximab tesirine,,"Hematopoietic protein binding antibody, ADC or cytotoxin",CD19-directed antibody-drug conjugate,CD19,Y,N,NA
2021,Melphalan flufenamide,,Cytotoxic chemotherapy,Alkylating agent,,N,N,NA
2021,Mobocertinib,EGFR Exon 20 Insertions,Small molecule kinase inhibitor,EGFR Exon 20 inhibitor,EGFR,Y,Y,Y
2021,Sirolimus,,Large molecule inhibitor,mTOR inhibitor,MTOR,Y,N,NA
2021,Sotorasib,KRAS G12C,Small molecule inhibitor,KRAS G12C inhibitor,KRAS,Y,Y,Y
2021,Tepotinib,MET Exon 14 Skipping Mutations,Small molecule kinase inhibitor,MET inhibitor,MET,Y,Y,Y
2021,Tisotumab vedotin,,Antibody drug conjugate,Tissue factor-directed antibody microtubule inhibitor conjugate,,Y,N,NA
2012,Regorafenib,KIT+,Multikinase inhibitor,"Multi-targeted tyrosine kinase inhibitor (targets include KIT, RET, VEGFR1/2/3, FGFR1/2, PDGFR? among others)",KIT;RET;FLT1;KDR;FLT3;FGFR1;FGFR2;PDGFR,Y,Y,Y
2021,Trastuzumab + Pembrolizumab,HER2+ (ERBB2 Amplification),Monoclonal antibody and immune checkpoint inhibitor combination,Anti-HER2 (ERBB2) antibody + Anti-PD-1 antibody,ERBB2;PDCD1,Y,Y,Y
2018,Gilteritinib,"FLT3 ITD Mutations, TKD Mutations I836 and D835",Small molecule kinase inhibitor,"Multi-targeted tyrosine kinase inhibitor (targets include mutant and WT FLT3, AXL and ALK)",FLT3;AXL;ALK,Y,Y,Y
2022,Adagrasib,KRAS G12C,Small molecule inhibitor,KRAS G12C inhibitor,KRAS,Y,Y,Y
2022,Ciltacabtagene autoleucel,,CAR T-cell therapy,CAR T-cell therapy (BCMA-directed),TNFRSF17,Y,N,NA
2022,Futibatinib,FGFR2 Fusions,Small molecule kinase inhibitor,FGFR1/2/3 inhibitor,FGFR1;FGFR2;FGFR3,Y,Y,Y
2022,Mirvetuximab soravtansine,FR?,Antibody drug conjugate,Folate receptor alpha-directed antibody microtubule inhibitor conjugate,,Y,Y,N
2022,Mosunetuzumab,,Bispecific T-cell engager,Bispecific CD20-directed CD3 T-cell engager,MS4A1,Y,N,NA
2022,Nadofaragene firadenovec,,Gene therapy,Adenoviral vector-based gene therapy carrying IFN?2b,IFN,Y,N,NA
2022,Nivolumab and relatlimab (Opdualag),,Immune checkpoint inhibitor,Anti-PD-1 antibody + Anti-LAG-3 antibody,PDCD1;LAG3,Y,N,NA
2022,Olutasidenib,IDH1 R132C/G/H/L/S,Small molecule inhibitor,IDH1 inhibitor,IDH1,Y,Y,Y
2022,Pluvicto,PSMA+,Radiotherapy,Radioligand therapeutic agent,,Y,Y,N
2022,Tebentafusp,HLA-A*02:01-positivity,Bispecific T-cell engager,Bispecific gp100 peptide-HLA-A*02:01-directed T-cell receptor CD3 T cell engager,,Y,Y,N
2022,Teclistamab,,Bispecific T-cell engager,Bispecific BCMA-directed CD3 T-cell engager,TNFRSF17,Y,N,NA
2022,Tremelimumab,,Immune checkpoint inhibitor,Anti-CTLA-4 antibody,CTLA4,Y,N,NA
2023,Capivasertib,"PIK3CA, AKT1 or PTEN Oncogenic Mutations and HR+/HER2-",Small molecule kinase inhibitor,AKT1/2/3 inhibitor,AKT1;AKT2;AKT3,Y,Y,Y
2023,Elacestrant,"ESR1 Ligand-binding domain missense mutations and
ER+/HER2-",Hormone therapy,Selective estrogen receptor degrader (SERD),ESR1;ESR2,Y,Y,Y
2023,Elranatamab,,Bispecific T-cell engager,Bispecific BCMA-directed CD3 T-cell engager,TNFRSF17,Y,N,NA
2023,Enfortumab vedotin + Pembrolizumab,,Antibody drug conjugate and immune checkpoint inhibitor combination ,Nectin-4-directed antibody and microtubule inhibitor conjugate + Anti-PD-1 antibody,NECTIN4;PDCD1,Y,N,NA
2023,Epcoritamab ,,Bispecific T-cell engager,Bispecific CD20-directed CD3 T-cell engager,MS4A1,Y,N,NA
2023,Fruquintinib,,Small molecule kinase inhibitor,VEGFR1/2/3 inhibitor,FLT1;KDR;FLT3,Y,N,NA
2023,Glofitamab,,Monoclonal antibody,CD20-CD3 bispecific antibody,MS4A1,Y,N,NA
2023,Pirtobrutinib,,Small molecule kinase inhibitor,BTK inhibitor,BTK,Y,N,NA
2023,Quizartinib,FLT3 ITD Mutations,Small molecule inhibitor,FLT3 inhibitor,FLT3,Y,Y,Y
2009,Pazopanib,,Multikinase inhibitor,"Multi-targeted tyrosine kinase inhibitor (targets include VEGFR1/2/3, PDGFR?/?, KIT, FGFR1/3 among others)",FLT1;KDR;FLT3;PDGFR;KIT;FGFR1;FGFR2;FGFR3,Y,N,NA
2023,Retifanlimab,,Immune checkpoint inhibitor,Anti-PD-1 antibody,PDCD1,Y,N,NA
2023,Talquetamab,,Bispecific T-cell engager,Bispecific GPRC5D-directed CD3 T-cell engager,GPRC5D,Y,N,NA
2023,Toripalimab,,Immune checkpoint inhibitor,Anti PD-1 antibody,PDCD1,Y,N,NA
2023,Eflornithine,,Small molecule inhibitor,Ornithine decarboxylase inhibitor ,,Y,N,NA
2024,Lifileucel ,,Other Immunotherapy,Tumor-infiltrating lymphocyte therapy,,Y,N,NA
2024,Nogapendekin alfa inbakicept,,Other Immunotherapy,Interleukin-15 (IL-15) antagonist,,Y,N,NA
2024,Tovorafenib,"BRAF Fusions, BRAF Rearrangement, BRAF V600 ",Small molecule kinase inhibitor,RAF inhibitor,RAF1,Y,Y,Y
2024,Tarlatamab,,Bispecific T-cell engager,Bispecific DLL3-directed CD3 T-cell engager,DLL3,Y,N,NA
2024,Imetelstat,,Telomerase inhibitor,Telomerase template antagonist,,Y,N,NA
2024,Afamitresgene autoleucel,"HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and MAGE-A4 antigen positive",T cell receptor (TCR) therapy,MAGE-A4-directed TCR therapy,MAGEA4,Y,Y,N
2024,Vorasidenib,"IDH1 R132H/C/G/S/L, IDH2 R172K/M/W/S/G",Small molecule inhibitor,IDH1/IDH2 inhibitor,IDH1;IDH2,Y,Y,Y
2024,Lazertinib + Amivantamab,"EGFR L858R, Exon 19 Deletions",Small molecule kinase inhibitor and monoclonal antibody combination,EGFR tyrosine kinase inhibitor + EGFR-MET bispecific antibody,EGFR;MET,Y,Y,Y
2024,Inavolisib + Fulvestrant + Palbociclib,"PIK3CA Oncogenic Mutations, HR+/HER2-",Small molecule inhibitor and hormone therapy combination,?-specific PI3K inhibitor + selective estrogen receptor degrader + CDK4/6 inhibitor,PI3K;CDK4;CDK6;ESR1;ESR2,Y,Y,Y
2024,Adagrasib + Cetuximab,KRAS G12C,Small molecule inhibitor and monoclonal antibody combination,KRAS G12C inhibitor + Anti-EGFR antibody,KRAS,Y,Y,Y
2024,Zolbetuximab,HER2- and CLDN18.2+,Monoclonal antibody,CDLN18.2-directed cytolytic antibody,CLDN18,Y,Y,N
2024,Obecabtagene autoleucel,,CAR T-cell therapy,CAR T-cell therapy (CD19-directed),CD19,Y,N,NA
2024,Revumenib,KMT2A Rearrangement,Small molecule inhibitor,Menin inhibitor,MEN1,Y,Y,Y
2024,Zanidatamab,HER2+ (ERBB2 Amplification),Monoclonal antibody,Anti-HER2 (ERBB2) antibody,ERBB2,Y,Y,Y
2024,Zenocutuzumab,NRG1 Fusion,Bispecific T-cell engager,Bispecific HER2/HER3-directed T-cell engager,ERBB2;ERBB3,Y,Y,Y
